What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? a structured evidence-based review

Pain Medicine

Volumn 9, Issue 4, 2008, Pages 444-459

  Fishbain, David A ^a,b,d   Cole, Brandly ^c,d   Lewis, John ^a,b   Rosomoff, Hubert L ^a,b,c,d   Rosomoff, R Steele ^a,b,c,d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Douglas Gardens   (United States)

^d Douglas Gardens   (United States)

Author keywords

Aberrant drug related behaviors; Abuse addictionon chronic opioid analgesic therapy exposure; Addiction; Chronic nonmalignant pain; Chronic opioid analgesic therapy; Drug abuse; Pain; Urine toxicology

Indexed keywords

ILLICIT DRUG; NARCOTIC ANALGESIC AGENT;

ALCOHOLISM; CHRONIC PAIN; DRUG ABUSE; DRUG EXPOSURE; EVIDENCE BASED MEDICINE; HEALTH BEHAVIOR; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; MEDICAL LITERATURE; OPIATE ADDICTION; PATIENT SELECTION; PRESCRIPTION; REVIEW; URINALYSIS;

EID: 44249119043     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2007.00370.x     Document Type: Review

References (106)

1. Dunbar SA, Katz NP. Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: Report of 20 cases. J Pain Symptom Manage 1996;11:163–71.
2. Cowan DT, Wilson-Barnett J, Griffiths P, et al. A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of longterm opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine. Pain Med 2005;6:113–21.
3. Tennant FS Jr, Uelmen GF. Narcotic maintenance for chronic pain. Medical and legal guidelines. Narc Maintenance 1983;73:81–94.
4. Tennant F, Robinson D, Sagherian A, Seecof R. Chronic opioid treatment of intractable, nonmalignant pain. Pain Manage 1988;Jan/Feb:18–26.
5. Taub A. Opioid analgesics in the treatment of chronic intractable pain of non-neoplastic origin. In: Kitahata LM, Collins JD, eds. Narcotic Analgesics in Anesthesiology. Baltimore, MD: Williams & Wilkins; 1982:199–208.
6. Portenoy RK. Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage 1990;5:46– 62.
7. Tennant FS, Robinson D, Sagherian A, et al. Chronic opioid treatment of intractable, nonmalignant pain. NIDA Res Monogr 1988;81:174– 80.
8. Schaffer-Vargas G, Schaffer S, Mejia A, Fernandez C. Opioid for non-malignant pain experience of Venezuelan Center, 9th World Congress on Pain. 1999;289:345.
9. Urban BJ, France RD, Steinberger EK, Scott DL, Maltbie AA. Long-term use of narcotic/antide-pressant medication in the management of phantom limb pain. Pain 1986;24:191–6.
10. Zenz M, Strumpf M, Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 1992;7: 69–77.
11. Milligan K, Lanteri-Minet M, Borchert K, et al. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain 2001;2:197–204.
12. Moulin DE, Iezzi A, Amireh R, et al. Randomised trial of oral morphine for chronic non-cancer pain. Lancet 1996;347:143–7.
13. Porter J, Jick HN. Addiction rare in patients treated with narcotics. N Engl J Med 1980; 302:123.
14. Doquang-Cantagrel N, Magnuson SK, Wallace MS. Tolerability and efficacy of opioids in chronic nonmalignant pain. Addiction 1991; 722:129.
15. Bouckoms AJ, Masand P, Murray GB, et al. Chronic nonmalignant pain treated with long-term oral narcotic analgesics. Ann Clin Psychiatry 1992;8:185–92.
16. Jamison RN, Raymond SA, Slawsby EA, Nedeljk-ovic SS, Katz NP. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine 1998;23:2591–600.
17. France RD, Urban BJ, Keefe FJ. Long-term use of narcotic analgesics in chronic pain. Soc Sci Med 1984;19:1379–82.
18. Kell MJ. Long-term methadone maintenance for intractable, nonmalignant pain: Pain control and plasma opioid levels. AJPM 1994;4:10–6.
19. Cowan DT, Wilson-Barnett J, Griffiths P, Allan LG. A survey of chronic noncancer pain patients prescribed opioid analgesics. Pain Med 2003; 4:340–51.
20. Mullican WS, Lacy JR. Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: A comparative trial. Clin Ther 2001;23:1429–44.
21. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal anti-inflam-matory drugs: A double blind, randomized, multi-center, placebo controlled trial. J Rheumatol 1999;26:4.
22. Kjaersgaard-Andersen P, Nafei A, Skov O, et al. Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip. A randomized, double-blind, multi-centre study. Pain 1990;43:309–18.
23. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain 2004;112:372–80.
24. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trials. JAMA 2005;293:3043–52.
25. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006;3:CD006146.
26. Furlan A, Sandoval J, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. CMAJ 2006;174:1589–94.
27. Martell BA, O’Connor PG, Kerns RD, et al. Systemic review: Opioid treatment for chronic back pain; prevalence, efficacy, and association with addiction. Ann Intern Med 2007;146:116–27.
28. Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic nonmalignant pain. Curr Med Res Opin 2005;21:1555–68.
29. Bloodworth D. Issues in opioid management. Am J Phys Med Rehabil 2005;84:S42–55.
30. Nicolas MK, Molloy AR, Brooker C. Using opioids with persisting noncancer pain: A biopsychoso-cial perspective. Clin J Pain 2006;22:137–46.
31. Fishbain DA, Rosomoff HL, Rosomoff RS. Drug abuse, dependence and addiction in chronic pain patients. Clin J Pain 1992;8:77–85.
32. Portenoy R. Opioid therapy for chronic nonmalignant pain: A review of the critical issues. J Pain Symptom Manage 1996;11:203–17.
33. Aronoff G. Opioids in chronic pain management: Is there a significant risk of addiction? Curr Rev Pain 2000;4:112–21.
34. Wasan A, Correll D, Kissin I, O’Shea S, Jamison R. Iatrogenic addiction in patients treated for acute or subacute pain: A systematic review. J Opioid Manage 2006;2:16–22.
35. Bartleson JD. Evidence for and against the use of opioid analgesics for chronic nonmalignant low back pain: A review. Pain Med 2002;3:260–71.
36. Jaffee J. Opiates: Clinical aspects. In: Lowenson J, Ruiz P, Mullman R, eds. Substance Abuse, A Comprehensive Text. Baltimore, MD: Williams & Wilkins; 1992:186–94.
37. Passik SD, Kirsh KL, Whitcomb L, et al. Monitoring outcomes during long-term opioid therapy for noncancer pain: Results with the pain assessment and documentation tool. J Opioid Manage 2005;1:5.
38. Chabal C, Erjavec M, Jacobson L, Mariano A, Chaney E. Prescription opiate abuse in chronic pain patients: Clinical criteria, incidence, and predictors. Clin J Pain 1997;13:150–5.
39. Manchikanti L, Fellows B, Damron KS, Pampati V, McManus CE. Prevalence of illicit drug use among individuals with chronic pain in the Commonwealth of Kentucky: An evaluation of patterns and trends. J Ky Med Assoc 2005;103:55– 62.
40. Vaglienti RM, Huber SJ, Noel KR, Johnstone RE. Misuse of prescribed controlled substances defined by urinalysis. W V Med J 2003;99:67–70.
41. Schulzeck S, Gleim M, Maier C. Factors contributing to the results of long-term treatment with oral morphine tablets in patients with chronic non-malignant pain. Anaesthetist 1993;42:545–56.
42. Kell M. Monitoring compliance with OxyContin Rx in 14,712 patients treated in 127 outpatient pain centers. Pain Med 2005;6:186–7.
43. Katz NP, Sherburne S, Beach M, et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003;97:1097–102.
44. Belgrade MJ, Ismail M, Yoon M, Panopoulos G. Non-compliant drug screens during opioid maintenance analgesia for chronic non-malignant pain. Am Pain Society Meeting, 2001. San Diego A# 787, p. 42.
45. Chapman C, Hill H. Prolonged morphine self-administration and addiction liability. Evaluation of two theories in a bone marrow transplant unit. Cancer 1989;63:1636–44.
46. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842–6.
47. Rangel-Guerra R. An open evaluation of oral butorphanol as long-term therapy in out-patients suffering from moderate to severe chronic pain. J Int Med Res 1981;9:120–3.
48. Manchikanti L, Vidyasagar P, Damron K, et al. Prevalence of opioid abuse in interventional pain medicine practice settings: A randomized clinical evaluation. Pain Physician 2001;4:358–65.
49. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: A prospective cohort study. BMC Health Serv Res 2006;6:46.
50. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain. Report of 38 cases. Pain 1986;25:171–86.
51. Dellemijn PLI, van Duijn H, Vanneste JAL. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 1998;16:220–9.
52. Burchman SL, Pagel PS. Implementation of a formal treatment agreement for outpatient management of chronic nonmalignant pain with opioid analgesics. J Pain Symptom Manage 1995;10:556– 63.
53. Arkinstall W, Sandler A, Goughnour B, et al. Efficacy of controlled-release codeine in chronic nonmalignant pain: A randomized, placebo-controlled clinical trial. Pain 1995;62:169–78.
54. Broughton AN, Gordon DN, Miller AJ. Long term tolerability of cr oxycodone (OxyContin tablets) in 101 patients treated for 12 months. World Congress On Pain, 1999, 339.
55. Simpson RK Jr, Edmondson EA, Constant CF, Collier C. Transdermal fentanyl as treatment for chronic low back pain. J Pain Symptom Manage 1997;14:218–24.
56. Wan Lu C, Urban B, France RD. Long-term use of narcotic analgesics in chronic pain. Soc Sci Med 1988;19:1379–82.
57. Portenoy RK. Chronic opioid therapy for nonmalignant pain: From models to practice. APS J 1992;1:285–8.
58. Kell MJ, Musselman DL. Methadone prophylaxis of intractable headaches: Pain control and serum opioid levels. AJPM 1993;3:7–14.
59. Ytterberg SR, Mahowald ML, Woods SR. Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis Rheum 1998;41:1603– 12.
60. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322:1–7.
61. Cowan DT, Allan L, Griffiths P. A pilot study into the problematic use of opioid analgesics in chronic non-cancer pain patients. Int J Nurs Stud 2002; 39:59–69.
62. McIlwain H, Ahdieh H. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain. A one year study. Am J Ther 2005;12:106–12.
63. Chao J. Retrospective analysis of Kadian (mor-phine sulfate sustained-release capsules) in patients with chronic, nonmalignant pain. Pain Med 2005;6:262–5.
64. Matsumoto A, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: Results of a randomized, double-blind, pla-cebo-and active-controlled phase III trial. Pain Med 2005;6:357–66.
65. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Med 2005;6:432–42.
66. Richarz A, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Spine 2005;30:2484–90.
67. Watson C, Peter N, Babul N. Efficacy of oxycodone in neuropathic pain: A randomized trial in postherpetic neuralgia. Neurology 1998;50:1837– 41.
68. Roth SH, Fleischman RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain. Arch Intern Med 2000;160:853–60.
69. Markenson JA, Zhang CJ, Richards P. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 2005;21:524–35.
70. Gimbel JS, Richards P, Portenoy RK Controlled-release oxycodone for pain in diabetic neuropathy. A randomized controlled trial. Neurology 2003; 60:927–34.
71. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia. A randomized, placebo-controlled trial. Neurology 2002;59:1015–21.
72. Huse E, Larbig W, flor H, Birbaumer N. The effect of opioids on phantom limb pain and cortical reorganization. Pain 2001;90:47–55.
73. Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, Pappagallo M. Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage 1998;15:185–94.
74. Quang-Cantagrel Nathalie D, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: A chart Review. Anesth Analg 2000;90:933–7.
75. Schofferman J. Long-term opioid analgesic therapy for severe refractory lumbar spine pain. Clin J Pain 1999;15:136–40.
76. Salzman RT, Brobyn RD. Long-term comparison of suprofen and propoxyphene in patients with osteoarthritis. Pharmacology 1983;27(suppl 1):55– 64.
77. Peloso PM, Bellamy N, Bensen W, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 2000;27:3.
78. Wilder-Smith CH, Hill L, Spargo K, Kalla A. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAIDs: A randomized study comparing analgesia, antinociception and gastrointestinal effects. Pain 2001;91:23–31.
79. Palangio M, Damask MJ, Morris E, et al. Combination hydrocodone and ibuprofen versus combination codeine and acetaminophen for the treatment of chronic pain. Clin Ther 2000;22:879– 92.
80. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain. Results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002;23:278–91.
81. Mystakidou D, Parpa E, Tsilika E, et al. Long-term management of noncancer pain with transdermal therapeutic system––Fentanyl. J Pain 2003;4:298–306.
82. Watson CPN, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71–8.
83. Zimmerman M, Waap I. Individual aspects of the quality of life of patients with chronic pain. Observational study of treatment with fentanyl-TTS. MMW Fortschr Med 2005;147(suppl 1):33–40.
84. Manchikanti L, Manchukonda R, Pampati V, et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician 2006;9:123–9.
85. Rowbotham MC, Twilling L, Davies P, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348:1223–32.
86. Parr G, Darekar B, Fletcher A, Bulpitt C. Joint pain and quality of life: Results of a randomized trial. Br J Clin Pharmacol 1989;27:235–42.
87. Rhodin A, Gronbladh L, Nilsson LH, Gordh T. Methadone treatment of chronic non-malignant pain and opioid dependence—A long-term follow-up. Eur J Pain 2006;10:271–8.
88. ® (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions––The ACCPT Study. Pain Pract 2006;6:254–64.
89. Michna EJ, Ross EL, Janfaza D, et al. Urine toxicology screening among chronic pain patients on opioid therapy: Frequency and predictability of abnormal findings. Clin J Pain 2007;23:173–9.
90. Institute of Medicine Committee to advise Public Health Service on Clinical Practice. Clinical Practice Guidelines Directions for a New Program. Washington, DC: National Academy Press; 1990.
91. Hoogendoorn WE, van Poppel MN, Bongers PM et al. Systematic review of psychosocial factors at work and private life as risk factors for back pain. Spine 2000;25:2114–25.
92. De Vet H, de Bie R, vender Heijden G, et al. Systematic reviews on the basis of methodological criteria. Physiotherapy 1997;83:284–9.
93. Borghouts JA, Koes BW, Bouter LM. The clinical course and prognostic factors of non-specific neck pain: A systematic review. Pain 1998;77:1–13.
94. Kirsh K, Whitcomb L, Donaghy K, Passik S. Abuse and addiction issues in medically ill patients with pain: Attempts at clarification of terms and empirical study. Clin J Pain 2002;18:S52–60.
95. Cowan D. Problematic terminology for problematic drug use. J Opioid Manage 2006;2:23–30.
96. Fishbain DA. Chronic pain and addiction, chapter 10. In: Boswell MV, Cole BE, eds. Weiner’s Pain Management, A Practical Guide for Clinicians, 7th edition. Boca Raton, FL: CRC Press; 2006:117– 39.
97. Li V, Katragadda R, Mosuro Y, Friedman R. Pain and addiction: Screening patients at risk. Pain Med 2001;2:244,A216.
98. Sees K, DiMarino M, Ruediger N, Sweeney C, Shiffman S. Non-medical use of OxyContin tablets in the United States. J Pain Palliat Care Pharmacother 2005;19:13–23.
99. Smith M, Woody G. Nonmedical use and abuse of scheduled medications prescribed for pain, pain-related symptoms, and psychiatric disorders: Patterns, user characteristics, and management options. Curr Psychiatry Rep 2005;7:337–43.
100. Nurnberger J, Foroud T, Flury L, et al. Evidence for a locus on chromosome 1 that influences vulnerability to alcoholism and affective disorder. Am J Psychiatry 2001;158:718–24.
101. Passik S, Kirsh K, Whitcomb L, Dickerson P, Theobald D. Pain clinicians’ rankings of aberrant drug-taking behaviors. J Pain Palliative Care 2002;16:39–49.
102. Weissman DE, Haddox JD. Opioid pseudoaddiction: An iatrogenic syndrome. Pain 1989;36:363– 6.
103. Ferrari A, Cicero AF, Bertolini A, Pasciullo G, Sternieri E. Need for analgesics/drugs of abuse: A comparison between headache patients and addicts by the Leeds Dependence Questionnaire (LDQ). Cephalgia 2006;26:187–93.
104. Elander J, Lusher J, Bevan D, Telfer P, Burton B. Understanding the causes of problematic pain management in sickle cell disease: Evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. J Pain Symptom Manage 2004;27:156–69.
105. Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain 2002;18(4 suppl): S76–82.
106. Lusher J, Elander J, Bevan D, Telfer P, Burton B. Analgesic addiction and pseudoaddiction in painful chronic illness. Clin J Pain 2006;22:316–24.